Across TCGA pan-cancer cohorts, ARL9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARL9 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher ARL9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARL9 expression acts as an unfavorable survival marker.

CESC, SKCM, and BLCA are the cancer types where ARL9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.146	0.740	<.001	12	view →
SKCM	OS	Median	All	0.351	0.783	.016	6	view →
BLCA	OS	Median	III,IV	0.239	0.683	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ARL9 tumor-vs-normal RNA expression · all ARL9 data types